Gujarat Themis Biosyn Ltd
GUJTHEM
Company Profile
Business description
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
Contact
S.V Road
Themis House, 11/12 Udyog Nagar
Goregaon (West)
MumbaiMH400104
INDT: +91 2267607080
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
265
Stocks News & Analysis
stocks
We take a different view to market on ASX bloodbath
Sales growth at CSL was lower than expected but streamlining the business has its perks.
stocks
BHP earnings weaker with lower iron ore prices more than offsetting higher copper volumes
Results were softer than expected.
stocks
Moated ASX player makes moves to support growth in China
a2Milk announced an acquisition and a divestiture as it aims to take a bigger slice of China’s baby formula market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,170.80 | 3.00 | -0.03% |
| CAC 40 | 7,979.08 | 95.03 | 1.21% |
| DAX 40 | 24,423.07 | 108.30 | 0.45% |
| Dow JONES (US) | 44,922.27 | 10.45 | 0.02% |
| FTSE 100 | 9,189.22 | 31.48 | 0.34% |
| HKSE | 24,976.95 | 145.95 | -0.58% |
| NASDAQ | 21,314.95 | 314.82 | -1.46% |
| Nikkei 225 | 42,880.53 | 665.76 | -1.53% |
| NZX 50 Index | 13,071.30 | 142.62 | 1.10% |
| S&P 500 | 6,411.37 | 37.78 | -0.59% |
| S&P/ASX 200 | 8,910.20 | 14.00 | 0.16% |
| SSE Composite Index | 3,728.18 | 0.89 | 0.02% |